针对勃起功能障碍的注射治疗的综合史,1982-2023年
Hartmut Porst1, Ronald Lewis2, Ronald Virag3
1European Institute for Sexual Medicine, Hamburg 20095, Germany.
Sexual medicine reviews
|April 21, 2024
概括
针对勃起功能障碍 (ED) 的自我注射疗法在40年后提供了高效率和可靠性. 对于那些对口服药物无反应的患者来说,它仍然是关键的治疗选择.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 性医学性医学性医学性医学
- 医学史 医学史 医学史
背景情况:
- 口服化酶5抑制剂是勃起功能障碍 (ED) 的一线治疗方法,但不适合所有患者.
- 用血管活性药物的自我注射疗法是ED患者的可行替代方案,这些患者不能容忍或不对口服疗法做出反应.
- 针对ED的注射治疗的历史可以追溯到1982年.
研究的目的:
- 为提供对ED的自我注射治疗的全面历史审查.
- 记录注射治疗从1982年开始的演变.
- 根据历史记录和文献,更新自我注射治疗的现状.
主要方法:
- 从1982年到2023年6月使用PubMed和Medline对ED注射治疗的已公布数据的全面审查.
- 包括来自早期注射治疗的先驱和目击者的第一手叙述.
- 彻底审查与注射治疗相关的治疗报告,副作用和并发症.
主要成果:
- 主要的先驱者及其贡献:罗纳尔·维拉格 (papaverine,1982年),吉尔斯·布林德利 (phentolamine/phenoxybenzamine,1983年),阿德里安·佐格尼奥蒂 (papaverine/phentolamine,1985年) 和甘森·阿达肯/N. 石井 (前列腺在E1,1986年).
- 莫克西西莱特 (thymoxamine) 是一个早期的药物,但后来被撤回.
- 偏爱症是最常见的副作用,帕帕维林构成最大的风险. 前列腺素E1和三合物是当前的首选药物;阿维普塔迪尔/芬托胺是最近的发展.
结论:
- 在40年后,自我注射疗法在治疗勃起功能障碍方面表现出最高的疗效和可靠性率.
- 它仍然是对夫妇管理ED的重要和有效的治疗选择.
- 注射疗法的历史发展是广泛和重要的.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
Disorders of the Male Reproductive System
402
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
402
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Administration and Therapy Phases: Overview
454
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
454
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170


